Skip to main content
Premium Trial:

Request an Annual Quote

DeCode Slashes Loss, See Slight Gain in Revenues

NEW YORK, Aug. 13 (GenomeWeb News) - DeCode Genetics slashed its net loss nearly by half for the second quarter and reported narrow revenue growth today.


The company had revenue of $10.5 million for the second quarter, ending June 30, compared to $9.4 million for the year-ago quarter. Net loss was $10.2 milllion, compared to $19.7 million for the same period in 2002.


The firm cut its research and development expenditures to $16.7 million for the quarter, compared to $24 million for the second quarter, 2002.


The Iceland-based firm said it has $77 million in cash and cash equivalents at the close of the quarter on June 30.


The company said it had $12.7 million in deferred revenue, which will be recognized in future reporting periods.


The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.